stoxline Quote Chart Rank Option Currency Glossary
  
VivoSim Labs, Inc. (VIVS)
0.14335  0.002 (1.24%)    11-09 16:00
Open: 0.1401
High: 0.1487
Volume: 333,296
  
Pre. Close: 0.1416
Low: 0.14
Market Cap: 2(M)
Technical analysis
2026-11-09 4:43:42 PM
Short term     
Mid term     
Targets 6-month :  0.21 1-year :  0.24
Resists First :  0.18 Second :  0.2
Pivot price 0.15
Supports First :  0.14 Second :  0.11
MAs MA(5) :  0.14 MA(20) :  0.15
MA(100) :  0.39 MA(250) :  1.23
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  4.1 D(3) :  6.2
RSI RSI(14): 35.1
52-week High :  3.4 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VIVS ] has closed above bottom band by 29.1%. Bollinger Bands are 80.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.15 - 0.15 0.15 - 0.15
Low: 0.14 - 0.14 0.14 - 0.14
Close: 0.14 - 0.14 0.14 - 0.14
Company Description

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Headline News

Fri, 06 Nov 2026
VivoSim Labs, Inc. (VIVS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sat, 24 Oct 2026
VivoSim Labs, Inc. Estimates – NASDAQ:VIVS - TradingView

Wed, 21 Oct 2026
VivoSim Labs Extends NAMkind Platform with Human Disease - GlobeNewswire

Wed, 07 Oct 2026
Human-cell tests can flag liver risks before clinical trials, VivoSim says. - Stock Titan

Wed, 07 Oct 2026
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods - GlobeNewswire

Tue, 01 Sep 2026
VivoSim Labs (VIVS) CCO buys 10,000 shares outside trading plan - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 17 (M)
Held by Insiders 1.446e+007 (%)
Held by Institutions 2.6 (%)
Shares Short 565 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.114e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -15 %
Return on Assets (ttm) 327.7 %
Return on Equity (ttm) -89.5 %
Qtrly Rev. Growth 112000 %
Gross Profit (p.s.) -32.95
Sales Per Share -219.94
EBITDA (p.s.) -2.69872e+006
Qtrly Earnings Growth -4.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -0.31
Stock Dividends
Dividend 0
Forward Dividend 598420
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android